ArticlePeerJ2026
Serum ferritin as a potential biomarker for distinguishing advanced-stage colorectal cancer: a retrospective cohort study.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron Metabolism in the Colorectal Tumor Microenvironment: Current Evidence and Clinical Implications.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) stage plays a major role in treatment decisions and prognosis. This study investigates whether Serum Ferritin can improve CRC staging and compares its performance to standard markers like carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA). Methods: We analyzed data from 419 CRC patients at Jiujiang College Affiliated Hospital, dividing them into early-stage (I-II, 245 patients) and late-stage (III-IV, 174 patients) groups. Logistic regression and receiver operating characteristic (ROC) curves were used to assess the usefulness of serum ferritin compared with traditional markers. Results: Serum Ferritin was significantly higher in late-stage CRC ( Conclusion: Serum Ferritin could be a useful addition to CRC staging, showing a numerically higher AUC than current markers. Adding it to clinical practice may help refine stage assessment and guide treatment decisions. This study supports its potential as a supplementary tool for stage assessment in CRC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.